|
|
You are here: Knowledge Base >
|
Beta Glucan Resource Center Last Updated: 12/23/2014 |
|
Beta Glucan Resource Center Here you will find links to articles, studies, and audio and video presentations to help you better understand Beta glucan and how it works to support your immune system VIDEO/AUDIO (Interviews range from approximately 15-30 minutes each) Beta Glucan and the Immune System - VIDEO Mode of Action - VIDEO A.J. Lanigan Interview - Beta Glucan - AUDIO Health, Wealth and Happiness Radio Talk Show hosted by: Gary Pozsik Sharon T. Lewis, R.N. Interview - Beta Glucan - AUDIO Health, Wealth and Happiness Radio Talk Show hosted by: Gary Pozsik ARTICLES History of Beta Glucan Why Transfer Point is the Best Beta Glucan Beta Glucan JANA Studies, 2007 Beta Glucan - Medlines Beta Glucan and Nuclear Radiation Quotes about Beta Glucan Transfer Point Beta Glucan (Glucan 300®) versus Our Health Co-op Comparison chart Transfer Point Beta Glucan (Glucan 300®) versus Wellmune WGP Comparison Chart Biological Activity of Transfer Point’s Glucan 300® PUBLISHED RESEARCH Note - The Gucan #300 named in the following research papers refers to the patent name for Transfer Point Beta 1, 3D Glucan. 2011 - Beta Glucan - Immunostimulant, Adjuvant, Potential Drug World Journal of Clinical Oncology, February 2011 Download entire article in .pdf format 2010 - Beta 1,3-Glucan: Silver Bullet or Hot Air? Open Glycoscience, 2010 Download entire article in .pdf format 2010 - Beta Glucan and Humic Acid: Synergistic Effects on the Immune System Journal of Medicinal Food, 13 (4) 2010 Download entire article in .pdf format 2009 - Beta Glucan -Indomethacin Combination Produces No Lethal Effects Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. Download entire article in .pdf format 2008 - A Comparison of Injected and Orally Administered B-glucans JANA Vol 11, No. 1, 2008 October 2007 - Physiological Effects Of Different Types of Beta Glucan Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. March 2007 - An Evaluation of the Immunological Activities of Commercially Available β1, 3-Glucans JANA Vol.10, No. 1, 2007 September 2005 -Beta-Glucan Enhances Complement-Mediated Hematopoietic Recovery after Bone Marrow Injury Blood First Edition Paper June 2005 -C5a-Mediated Leukotriene B4-Amplified Neutrophil Chemotaxis is Essential in Tumor Immunotherapy Facilitated by Anti-Tumor Monoclonal Antibody and ß-Glucan The Journal of Immunology 2005 174:7050-7056 September 2004 - ß-Glucan Affects Leukocyte Navigation in a Complex Chemotactic Gradient Surgery 2004: 136:384-89 July 15, 2004 - Mechanism by
Which Orally Administered ß-1,3-Glucans Enhance the Tumorcidial
Activity of Anti-Tumor Monoclonal Antibodies in Murine Tumor Models The Journal of Immunology 2004: 173: 797-806 December
15, 2003 - ß-Glucan Functions as an Adjuvant for Monoclonal Antibody
Immunotherapy by Recruiting Tumoricidal Granulocytes as Killer Cells Cancer Research 63, 9023-9031, Dec. 15, 2003 A Journal of the American Association for Cancer Research (See below for important information) Download the entire article in .pdf format Promising
initial study results demonstrate that a soluble beta glucan compound
significantly increased the effectiveness of monoclonal antibodies
specific for the treatment of breast, liver and lung cancer, according
to a recent article published in Cancer Research, a journal of the
American Association for Cancer Research.
In a series of
preclinical studies, a therapeutic combination of a patented, soluble
yeast beta glucan called NSG and monoclonal antibodies significantly
enhanced both tumor regression and long-term survival as compared with
monoclonal antibody therapy alone. In the breast cancer model, 40
percent of the mice receiving the combined therapy survived long-term
and tumor-free, compared with no survivors among mice treated with the
monoclonal antibody or NSG alone. Similarly, in a liver cancer model the
combined therapy extended survival and increased long-term survivorship
by 25 percent.
“The data
suggests that the therapeutic efficacy of certain complement-activating
monoclonal antibodies, like Herceptin, Rituxan and Erbitux, could be
significantly enhanced if they were combined with NSG,” said Gordon D.
Ross, Ph.D., Director of the Tumor Immunobiology Program at the James
Graham Brown Cancer Center located at the University of Louisville and
the senior author of the paper. “Given the limited tumor-killing
mechanisms available to monoclonal antibodies, soluble beta glucan
engages another arm of the immune system to fight cancer. NSG is a
potentially important adjuvant to monoclonal antibodies for enhancing
long-term cancer survival by providing this additive effect to these
immunotherapies.”
NSG
effectively recruits neutrophils, which are innate immune cells, to
engage in tumoricidal activities. Normally, these white blood cells do
not engage in the fight against cancer cells since they are viewed as
“self,” only respond to “nonself” cells. Dr. Ross discovered that NSG, a
polysaccharide derived from a proprietary strain of yeast, binds to a
specific receptor site on these innate immune cells, allowing them to
“see” the cancer as “nonself” and trigger killing.
“This is
notable research published in a very well respected medical journal
devoted to cancer research. Other work performed by Dr. Ross and his
colleagues have demonstrated that orally dosed Beta 1,3-D glucan is
taken up by macrophages and neutrophils via the Peyer’s Patches in the
gut. In a period of 3-12 days, these phagocytes digest the insoluble
particles and convert them into a soluble form of beta glucan. We would
encourage everyone to take this article and share it with physicians and
particularly oncologists working with different forms of
immunotherapy”.
1 – Cancer Research 63, 9023-9031 December 2003 March 24, 2003 - Anthrax-Protective Effects of Yeast Beta 1,3 Glucans
Medscape General Medicine
May
1, 2002 - Pilot Study: Orally-Administered Yeast ß1,3-glucan
Prophylactically Protects Against Anthrax Infection and Cancer in Mice
The Journal of the American Nutraceutical Association Vol. 5, No. 2, Spring 2002
|